

World Journal of *Hepatology*

World J Hepatol 2017 October 8; 9(28): 1133-1140



**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 1133** Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions

Selva Rajoo A, Lim SG, Phyo WW, Tun T, Dan YY, Lee YM, Low HC, Lim K, Tan PS, Lee GH

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Valerio Nobili, MD, Associate Professor, Hepatometabolic Unit and Liver Research Laboratory, Liver Unit, Research Institute, Bambino Gesù Children's Hospital, Rome 00197, Italy

AIM AND SCOPE

World Journal of Hepatology (*World J Hepatol*, *WJH*, online ISSN 1948-5182, DOI: 10.4254), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJH covers topics concerning liver biology/pathology, cirrhosis and its complications, liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. Priority publication will be given to articles concerning diagnosis and treatment of hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJH*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Hepatology is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, and Scopus.

FLYLEAF

I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fung-Fung Ji*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
36 Issues/Year (8th, 18th, and 28th of each month)

EDITORS-IN-CHIEF
Clara Balsano, PhD, Professor, Departement of Biomedicine, Institute of Molecular Biology and Pathology, Rome 00161, Italy

Wan-Long Chuang, MD, PhD, Doctor, Professor, Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com>

www.wjgnet.com/1948-5182/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Hepatology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238243
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
October 8, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Retrospective Cohort Study

Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions

Anandraj Selva Rajoo, Seng-Gee Lim, Wah Wah Phyto, Thandar Tun, Yock-Young Dan, Yin-Mei Lee, How-Cheng Low, Kieron Lim, Poh-Seng Tan, Guan-Huei Lee

Anandraj Selva Rajoo, Seng-Gee Lim, Yock-Young Dan, Guan-Huei Lee, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore

Seng-Gee Lim, Institute of Molecular and Cell Biology, ASTAR, Singapore 138668, Singapore

Seng-Gee Lim, Wah Wah Phyto, Yock-Young Dan, Yin-Mei Lee, How-Cheng Low, Kieron Lim, Poh-Seng Tan, Guan-Huei Lee, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore 119228, Singapore

Thandar Tun, Department of Hepatology, Mandalay General Hospital, 30th St, Chan Aye Tharsan Township, Mandalay, Myanmar

Author contributions: Lee GH contributed to study conception and design; Selva Rajoo A, Lim SG, Phyto WW, Tun T, Dan YY, Lee YM, Low HC, Lim K, Tan PS and Lee GH contributed to data acquisition, data analysis, and interpretation; Selva Rajoo A contributed to the writing of the article; Lim SG and Lee GH contributed to editing, reviewing and final approval of the article.

Institutional review board statement: The study was reviewed and approved by the National Healthcare Group Domain Specific Research Board.

Informed consent statement: Informed consent has been obtained from all eligible patients who can provide informed consent.

Conflict-of-interest statement: There are no existing or potential conflicts of interest for any of the investigators participating in this study and their immediate family members.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative

Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Guan-Huei Lee, MBBS, FRCP (Edin), PhD, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, Singapore 119228, Singapore. mdcleugh@nus.edu.sg
Telephone: +65-67725595
Fax: +65-67751518

Received: January 4, 2017

Peer-review started: January 7, 2017

First decision: March 13, 2017

Revised: July 23, 2017

Accepted: September 14, 2017

Article in press: September 15, 2017

Published online: October 8, 2017

Abstract

AIM

To explore the applicability of the Asia-Pacific Association for the Study of the Liver (APASL) and European Association for the Study of the Liver (EASL) guidelines for acute-on-chronic liver failure (ACLF) in profiling patients and determining the outcome.

METHODS

Patients admitted to a tertiary hospital in Singapore with acute decompensation of liver disease from January 2004

to July 2014 are screened for ACLF according to the APASL and EASL criteria. The patients' data (including basic demographics, information about existing chronic liver disease, information about the acute decompensation, relevant laboratory values during admission, treatment, and outcome) are retrospectively analyzed to determine the background, precipitating factors and outcome.

RESULTS

A total of 458 liver patients is analyzed, and 78 patients with ACLF are identified. Sixty-three patients (80.8%) meet the APASL criteria, 64 patients (82.1%) meet the EASL criteria, and 49 patients (62.8%) fulfilled both criteria. The most common causes of acute liver injury are bacterial infections (59.0%), hepatitis B flare (29.5%), and variceal bleeding (24.4%). The common aetiologies of the underlying chronic disease included hepatitis B (43.6%), alcoholic (20.5%) and cryptogenic (11.5%) liver disease. The overall mortality rate is 61.5%. Increased age, the number of organ failures (as per CLIF-SOFA score), peak creatinine, INR, and amylase levels are associated with increased mortality or the need for liver transplantation. 14.3% of patients undergo liver transplantation with a 100% 1-year survival rate.

CONCLUSION

Both APASL and EASL criteria have identified ACLF patients with high three-month mortality, but those who fulfill APASL criteria alone have a better survival.

Key words: Acute-on-chronic liver failure; Survival; Prognosis; Liver decompensation; Liver cirrhosis

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Acute-on-chronic liver failure (ACLF) is a distinct disease entity with a high short-term mortality. Utilizing both the Asia-Pacific Association for the Study of the Liver (APASL) and European Association for the Study of the Liver criteria, our study shows that the clinical profile of ACLF patients in Singapore appears to have mixed features compared with similar studies reported in the rest of Asia and the West. Patients with ACLF fulfilling only the APASL criteria in our study had significantly better survival rates. We also analyzed the prognostic factors of ACLF in our study.

Selva Rajoo A, Lim SG, Phyo WW, Tun T, Dan YY, Lee YM, Low HC, Lim K, Tan PS, Lee GH. Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions. *World J Hepatol* 2017; 9(28): 1133-1140 Available from: URL: <http://www.wjgnet.com/1948-5182/full/v9/i28/1133.htm> DOI: <http://dx.doi.org/10.4254/wjh.v9.i28.1133>

INTRODUCTION

Acute-on-chronic liver failure (ACLF) is a distinct disease

entity characterized by the acute deterioration of liver function in patients with chronic liver disease^[1]. It describes a condition in which two hepatic insults liver operate simultaneously, one of them being ongoing and persistent (e.g., chronic hepatitis C) while the other being an acute precipitating event (e.g., hepatotoxic drug, variceal bleed)^[2]. Patients with ACLF have a statistically higher mortality rate (30%-40%) compared with patients without ACLF, at the same baseline Model for End-Stage-Liver Disease (MELD) score^[3].

There are currently two widely accepted diagnostic criteria for ACLF: The Asia-Pacific Association for the Study of the Liver (APASL) in 2014^[2], and the European Association for the Study of the Liver (EASL) consensus definitions in 2011^[4]. Although these definitions describe the same disease entity, there are some crucial differences between them (summarised in Figure 1). APASL focuses more on signs of ascites and encephalopathy within a time frame of 4 wk with chronic liver disease. EASL underlines the occurrence of organ failure in patients with cirrhosis resulting in 3-mo mortality. Furthermore, these two definitions are based on populations with different disease patterns^[5].

The objectives of this study are first, to understand the clinical profile of the patients with ACLF in Singapore. From this, the precipitating risk factors for ACLF could be treated or prevented. Secondly, this study aims to analyze the prognostic indicators of ACLF thereby discussing ways to improve the outcome.

There is an increasing concern about ACLF, due to its high short-term mortality and lack of clear understanding of the natural history and clinical profile of the patients, which vary across different countries and regions in the world. This study provides preliminary data on the local ACLF patient profile and outcome of this condition. We also examined the relevance and applicability of the current two guidelines for ACLF diagnosis and prognosis in the local context.

MATERIALS AND METHODS

Study design

This retrospective cohort study was performed with existing data of patients admitted to the National University Hospital (NUH) in Singapore from January 2004 to July 2014. The data is part of an approved database of all patients admitted to the hepatology service or referred to liver transplant service. All patients were followed up for at least three months. All relevant data had been recorded in the hospital electronic medical records, Intensive Care Unit (ICU) monitoring system, and the patients' case files. In this study, the diagnosis of ACLF was made by utilizing either the APASL or EASL definitions.

Data collection

Data were retrospectively analyzed, but the clinicians prospectively collected the data through their inpatient lists and anonymously transferred to the study administrator.




Figure 1 Main differences between Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver criteria and the number of subjects fulfilling either or both criteria^[2,5,7]. APASL: Asia-Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver.

Confidentiality of the patients was preserved by anonymising the data collected. The subject data was assigned code numbers which do not reflect personal identifiers and were entered into a computerized database. Data collection included basic demographic information (age, gender, body mass index), information about existing chronic liver disease, information about acute decompensation, other relevant laboratory values of the patient during admission (white cell count, creatinine, bilirubin, international normalized ratio, C-reactive protein, etc.), treatment and outcome. This study protocol had been reviewed and approved by the National Healthcare Group Domain Specific Research Board (Domain E) (DSRB reference: 2014/01194).

Statistical analysis

Data entry and analysis were carried out using SPSS 20. Inter-group comparisons for categorical variables were made using the χ^2 test or Fisher's exact test, and those for quantitative variables were compared using the Student's *t*-test, one-way ANOVA. A *P*-value less than 0.05 was considered statistically significant.

RESULTS

A total of 458 liver patients were screened. One hundred and forty-seven were found to have an acute decompensation of chronic liver disease, and 78 of these patients were found to have ACLF that fulfilled either the APASL or EASL criteria. Sixty-three patients (80.8%) met the APASL criteria, and 64 patients (82.1%) met the EASL criteria. Forty-nine patients (62.8%) fulfilled both criteria (summarized in Figure 1 and Table 1).

Patient demographics

Table 1 shows the profile of patients with ACLF. The age range of the 78 patients included in the study was 55 to 61 years. Sixty-nine point two percent of these patients were Chinese, which is consistent with the local racial demographics of the population (74.3% Chinese, 13.4% Malays, and 9.1% Indians^[6]). Seventy-five point

five percent of the patients were male. Patients with ACLF meeting the EASL criteria were more likely to be older than those in the other two groups (*P* = 0.003).

Events leading to acute insult and underlying etiology

Bacterial infection (59.0%), hepatitis B flare (29.5%) and variceal bleeding (24.4%) were the most common causes leading to the acute insult. Patients fulfilling ACLF-EASL criteria were more likely to have had a bacterial infection triggering ACLF compared to those in the other two groups (*P* = 0.002). On the other hand, patients fulfilling ACLF-APASL criteria were more likely to have had hepatitis B flare triggering ACLF compared to those in the other two groups (*P* = 0.001). Patients admitted with ACLF most frequently have hepatitis B (43.6%), alcoholic liver disease (20.5%) and cryptogenic liver disease (11.5%) as their underlying chronic liver diseases. Patients fulfilling the APASL criteria were more likely to have Hepatitis B compared to patients in the EASL group.

Outcome

Table 2 shows the outcome of patients with Acute-on-Chronic Liver Failure. The overall mortality rate at the point of admission and three-month mortality rate were expectedly high at 57.7% and 61.5% respectively. Patients with ACLF fulfilling both criteria were more likely to have a fatal outcome at the point of admission (67.3% mortality) as well as in 3 mo [71.4% mortality (*P* = 0.033 and *P* = 0.041 respectively)]. Transplant rate was 14.3%, and all the transplant patients survived and lived for more than one year (*P* ≤ 0.0001).

Patients were further classified by ACLF grade (ACLF 0-3) according to the EASL-CLIF Consortium definitions^[5,7], which classifies the severity of ACLF by the number of organ failures^[8]. Table 3 shows information regarding organ failures, laboratory parameters and outcome of ACLF patients to the ACLF grade. Higher mortality rates were associated with an increased ACLF grade. Three-month mortality for ACLF 0 to 3 was 0%, 42.9%, 41.7% and 84.8% respectively. Patients with 3 or more organ failures (*i.e.*, ACLF 3) had a significantly higher mortality

Table 1 Profile of patients with acute-on-chronic liver failure *n* (%)

	APASL only (<i>n</i> = 14)	EASL only (<i>n</i> = 15)	Both (<i>n</i> = 49)	<i>P</i> value ³	Total (<i>n</i> = 78)
AGE (mean)	53 (48-57)	66 (61-71)	57 (54-60)	0.003	58 (55-61)
Race					
Chinese	9 (64.3)	9 (60)	36 (73.5)	0.171	54 (69.2)
Malay	1 (7.1)	2 (13.3)	5 (10.2)		8 (10.3)
Indian	0	3 (20)	5 (10.2)		8 (10.3)
Others	4 (28.6)	1 (6.7)	3 (6.1)		8 (10.3)
Male gender	12 (85.7)	11 (73.3)	36 (73.5)	0.625	59 (75.6)
Diabetes mellitus	7 (50)	5 (33.3)	16 (32.7)	0.478	28 (35.9)
Cause of acute liver injury ⁴					
Infection	4 (28.6)	14 (93.3)	28 (57.1)	0.002	46 (59)
Hepatitis B flare	9 (64.3)	0	14 (28.6)	0.001	23 (29.5)
Variceal bleeding	4 (28.6)	2 (13.3)	13 (26.5)	0.535	19 (24.4)
Unknown cause	2 (14.3)	1 (6.7)	8 (16.3)	0.642	11 (14.1)
Alcohol	1 (7.1)	0	5 (10.2)	0.429	6 (7.7)
TCM	1 (7.1)	0	5 (10.2)	0.429	6 (7.7)
TIPSS	0	0	1 (2)	0.741	1 (1.3)
Underlying chronic liver disease					
Hepatitis B	11 (78.6)	1 (6.7)	22 (44.9)	< 0.0001	34 (43.6)
Alcohol	2 (14.3)	3 (20)	11 (22.4)	0.799	16 (20.5)
Cryptogenic	0	3 (20)	6 (12.2)	0.234	9 (11.5)
Hepatitis C	0	2 (13.3)	3 (6.1)	0.339	5 (6.4)
NASH	0	2 (13.3)	2 (4.1)	0.23	4 (5.1)
Hepatitis B + alcohol	1 (7.1)	0	1 (2)	0.444	2 (2.6)
Others ¹	0	4 (26.7)	5 (10.2)	0.072	9 (11.5)
Liver cirrhosis	6 (42.9)	15 (100)	49 (100)	< 0.0001	70 (89.7)
HCC (Milan's criteria)	0	1 (6.7)	4 (8.2)	0.627	5 (6.4)
Other cancers ²	0	1 (6.7)	4 (8.2)		5 (6.4)
No malignancy	14 (100)	13 (86.7)	41 (83.7)		68 (87.2)
Previous decompensation	4 (28.6)	10 (66.7)	20 (43.5)	0.11	34 (45.3)

¹Other chronic liver diseases include Wilson's disease, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Congenital fibrosis, Drug-induced chronic liver disease and autoimmune liver disease; ²Other cancers: Colon cancer, renal cell carcinoma, bladder cancer and ovarian cancer; ³*P*-value of comparison of patients falling under APASL, EASL and both criteria; ⁴Patients may have more than one cause of acute liver injury. TCM: Traditional Chinese Medicine; TIPSS: Transjugular intrahepatic portosystemic shunt; NASH: Non-alcoholic steatohepatitis; HCC: Hepatocellular carcinoma; APASL: Asia-Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver.

Table 2 Outcome of patients with acute-on-chronic liver failure *n* (%)

	APASL only (<i>n</i> = 14)	EASL only (<i>n</i> = 15)	Both (<i>n</i> = 49)	<i>P</i> value	Total (<i>n</i> = 78)
MELD score (mean-range)	27 (23-31)	18 (13-23)	25 (22-28)	0.020	24 (33-26)
Transplant	4 (28.6)	0	7 (14.6)	0.089	11 (14.3)
Mortality (during admission)	4 (28.6)	8 (53.3)	33 (67.3)	0.033	45 (57.7)
Three month mortality	5 (35.7)	8 (53.3)	35 (71.4)	0.041	48 (61.5)

P value of comparison of patients falling under APASL, EASL and both criteria. APASL: Asia-Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver.

rate than all other patients at the point of admission and at three months ($P \leq 0.0001$, $P < 0.0001$ respectively). Patients who fulfill the APASL criteria for ACLF exclusively (*i.e.*, no organ failures or ALCF 0) had a 0% mortality rate.

The demographics, type of organ failure and laboratory parameters of ACLF patients who survived vs those who met a fatal outcome have been analyzed and summarised in Table 4. Patients with fatal outcomes were more likely to be older (mean age 60 vs 55, $P = 0.044$). Patients with renal (68.9%, $P = 0.001$), cerebral (37.8%, $P = 0.012$), circulatory (63.6%, $P \leq 0.0001$) and respiratory (17.8%, $P = 0.044$) failure were more likely to have a fatal outcome compared to those without these organ failures. Also, higher serum creatinine and

INR and baseline amylase were strongly associated with the poor prognosis compared to other laboratory tests ($P \leq 0.0001$, 0.018 and 0.026 respectively).

DISCUSSION

One of the compelling reasons for the lack of a unifying definition for ACLF is the difference in etiologies for both the acute insults and underlying chronic liver diseases in the East and West^[9], and much of this can be attributed to the socioeconomic status of the countries in Asia. In Singapore, with endemic chronic hepatitis B as the dominant chronic liver disease, coupled with a Westernised lifestyle and standard of living,

Table 3 Organ failures, laboratory parameters and outcome of acute-on-chronic liver failure patients with respect to acute-on-chronic liver failure grade *n* (%)

	ACLF0 (<i>n</i> = 6)	ACLF1 (<i>n</i> = 7)	ACLF2 (<i>n</i> = 24)	ACLF3 (<i>n</i> = 33) ¹	<i>P</i> value
Organ failures-clif-sofa score					
Liver	1 (16.7)	1 (14.3)	12 (50)	27 (81.8)	< 0.0001
Kidney	0	4 (57.1)	10 (41.7)	25 (75.8)	0.002
Cerebral	0	1 (14.3)	2 (8.3)	13 (39.4)	0.018
Coagulation	1 (16.7)	1 (14.3)	16 (66.7)	25 (75.8)	0.002
Circulation	0	0	7 (30.4)	26 (78.8)	< 0.0001
Respiration	0	0	2 (8.3)	7 (21.2)	0.22
Chronic renal disease	0	2 (28.6)	5 (20.8)	3 (9.1)	0.245
Laboratory data (mean)					
Leucocyte count at baseline, × 10 ⁹ /L	8 (6-11)	11 (6-16)	10 (7-12)	12 (10-13)	0.256
Platelet count at baseline	127 (42-212)	61 (40-82)	104 (78-129)	149 (105-193)	0.105
Bilirubin at baseline, mg/dL	7.0 (4.2-9.8)	7.7 (-3.1-18.5)	10 (4.9-15.1)	13.9 (9.9-17.8)	0.29
Peak bilirubin, mg/dL	11.3 (4.1-18.5)	10.7 (-4.2-25.5)	14.1 (9.1-19)	23 (18.7-27.3)	0.009
Creatinine at baseline, mg/dL	0.9 (0.4-1.3)	2.1 (1.3-2.9)	1.4 (1.1-1.8)	1.8 (1.1-2.4)	0.232
Peak creatinine, mg/dL	0.9 (0.5-1.2)	2.2 (1.4-3.1)	1.8 (1.4-2.1)	3.1 (2.6-3.7)	< 0.0001
Lactate at baseline, mmol/L	2.1 (1.4-2.7)	2.3 (2.1-2.6)	2.4 (1.7-3.2)	4.1 (2.4-5.7)	0.225
MELD score at baseline (mean)	23 (20-26)	21 (11-31)	20 (17-24)	26 (23-30)	0.113
Liver transplantation	1 (16.7)	0	6 (26.1)	1 (3)	0.043
Mortality during admission	0	3 (42.9)	10 (41.7)	28 (84.8)	< 0.0001
90-d mortality	0	3 (42.9)	11 (45.8)	29 (87.9)	< 0.0001

¹Only patients with cirrhosis were included in this analysis. *P*-value of comparison of patients with ACLF grade 0, 1, 2 and 3. ACLF: Acute-on-chronic liver failure.

understanding the mixed profiling of local ACLF patients and the prognostic factors will be important in better prevention and management of such high-risk patients.

Bacterial infection, hepatitis B flare, and variceal bleeding are the most common causes for the acute component of ACLF. Patients fulfilling the EASL criteria are more likely to have bacterial infections that triggered ACLF while patients meeting the APASL criteria are more likely to have a hepatitis B flare as the trigger. This difference is in keeping with the differences in underlying etiologies of acute deterioration of liver disease between the East and the West published in the literature. In the Asia-Pacific region, which is the demographic that the APASL guidelines are based upon, the majority of ACLF is precipitated by viral hepatitis. In developed European countries, these viral etiologies are mostly supplanted by non-viral insults such as bacterial infections^[10]. We note that more than half of the study population had a bacterial infection as the precipitating factor of ACLF, reflecting the developed health care standards enjoyed by the Singaporean population. There is no consensus as to whether variceal bleeding qualifies as a precipitant of ACLF under the APASL guidelines^[10]. However, this study shows that it is a prominent cause of ACLF (24.4%) should it be included.

Patients with ACLF in this study most frequently have chronic hepatitis B infection, alcoholic liver disease, and cryptogenic liver cirrhosis as their underlying chronic liver disease. The prevalence of HBV is expected given that Singapore lies within the Asia-Pacific region and in most Asian countries, hepatitis B constitutes about 70% of all chronic etiologies of ACLF. Alcoholic liver cirrhosis represents 50%-70% of all underlying etiologies of ACLF in Western countries^[5,11,12]. The fact that alcoholic

liver cirrhosis constitutes such a high proportion of the study population suggests a Western influence on the local community as well. However, some studies do indicate that alcohol-related ACLF is equally represented worldwide^[10,13].

One of the unexpected findings of this study is the narrow age range (52-64 years) of all 78 consecutive ACLF subjects. All 45 deaths were older (mean 60 years, range 56-64 years), with little overlap with the survivors (mean age 55 years, range 52-58 years) who were younger. Thus, a higher index of suspicion for progression to ACLF should be applied when patients above 50 years of age present with acute liver decompensation. Deterioration of the patient should be expected and pre-empted, especially for those between 55 to 65 years of age who are still eligible for liver transplantation. This age-related incidence and prognosis still await future validation studies for confirmation.

Patients with ACLF have a high mortality rate at 57.7% and 61.5% (at 0 and 3 mo respectively), which is comparable to the documented mortality rate of 50%-90%^[14]. Higher mortality rates have been associated with an increase in ACLF grade based on the CLIF-SOFA score (*i.e.*, more organ failures) in line with existing literature^[15]. Furthermore, patients with ACLF and no organ failure had a 0% mortality rate. These results suggest that the CLIF-SOFA organ failure score may be a useful predictor of death in our local ACLF population, in keeping with publications which identify the correlations between the number of organ failure(s) in patients with cirrhosis with mortality^[5]. In this study, peak creatinine, INR, and amylase levels are independently associated with increased mortality or the need for liver transplantation.

Table 4 Demographics, type of organ failure and laboratory parameters of acute-on-chronic liver failure patients with respect to outcome *n* (%)

	Deaths (<i>n</i> = 45)	Survivors (<i>n</i> = 33)	<i>P</i> value
Age (mean-range)	60 (56-64)	55 (52-58)	0.044 ¹
Liver transplantation	0	11 (34.4)	< 0.0001 ²
Race			
Chinese	33 (73.3)	21 (63.6)	0.004 ¹
Malay	6 (13.3)	2 (6.1)	
Indian	6 (13.3)	2 (6.1)	
Others	0	8 (24.2)	
Male gender	33 (73.3)	26 (78.8)	0.579 ¹
Diabetes mellitus	13 (28.9)	15 (45.5)	0.132 ¹
Previous hepatic decompensation	16 (37.2)	18 (56.2)	0.101 ¹
Potential events leading to acute insult			
Infection	28 (62.2)	18 (54.5)	0.496 ¹
Hepatitis B flare	15 (33.3)	8 (24.2)	0.384 ¹
Variceal bleeding	10 (22.2)	9 (27.3)	0.608 ¹
Unknown cause	5 (11.1)	6 (18.2)	0.287 ²
Alcohol	2 (4.4)	4 (12.1)	0.204 ²
TCM	5 (11.1)	1 (3)	0.189 ²
TIPSS	1 (2.2)	0	0.577 ²
Underlying chronic liver disease			
Hepatitis B	20 (44.4)	14 (42.4)	0.859 ¹
Alcohol	10 (22.2)	6 (18.2)	0.662 ¹
Cryptogenic	4 (8.9)	5 (15.2)	0.307 ²
Hepatitis C	3 (6.7)	2 (6.1)	0.646 ²
NASH	2 (4.4)	2 (6.1)	0.567 ²
Hepatitis B + alcohol	1 (2.2)	1 (3)	0.670 ²
Others ¹	6 (13.3)	3 (9.1)	0.419 ²
Liver cirrhosis	41 (91)	29 (87.9)	0.459 ²
HCC+ (Milan criteria)	3 (6.7)	2 (6.1)	0.709 ²
Other cancers ²	2 (4.4)	3 (9.1)	
None	40 (88.9)	28 (84.8)	
Organ failures-clif-sofa score			
Liver	31 (68.9)	17 (51.5)	0.119 ¹
Kidney	31 (68.9)	10 (30.3)	0.001 ¹
Cerebral	17 (37.8)	4 (12.1)	0.012 ¹
Coagulation	31 (68.9)	19 (57.6)	0.303 ¹
Circulation	28 (63.6)	7 (21.2)	< 0.0001 ¹
Respiration	8 (17.8)	1 (3)	0.044 ²
Chronic renal disease	9 (20)	2 (6.1)	0.075 ²
Leucocyte count at baseline (mean-range)	11 (10-12)	10 (8-12)	0.273 ³
Platelet count at baseline (mean-range)	135 (109-160)	120 (79-160)	0.528 ³
Amylase (mean-range)	117 (90-144)	72 (38-105)	0.026 ³
Maximal total bilirubin (mean-range)	20.2 (16.3-24)	15.9 (11.5-20.2)	0.137 ³
Maximal creatinine (mean-range)	2.9 (2.4-3.3)	1.6 (1.3-1.9)	< 0.0001 ³
Maximal INR (mean-range)	4.3 (3.5-5.1)	3 (2.5-3.6)	0.018 ³
MELD at baseline (mean-range)	26 (23-29)	22 (19-25)	0.119 ³
Lactate at baseline (mean-range)	3.5 (2.4-4.6)	2.8 (2-3.7)	0.311 ³

¹ χ^2 test; ²Fisher exact test; ³Independent *t*-test. TCM: Traditional Chinese Medicine; TIPSS: Transjugular intrahepatic portosystemic shunt; NASH: Non-alcoholic steatohepatitis; HCC: Hepatocellular carcinoma; APASL: Asia-Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver.

Peak creatinine level, in particular, is most strongly associated with increased mortality, which is expected given the association between renal failure and death in ACLF^{16]}.

Liver transplantation is an important definitive treatment for patients with severe ACLF, who usually have underlying liver cirrhosis^[17-20]. This study has shown that patients with ACLF who subsequently underwent liver transplantation had a 100% 1-year survival rate. This promising result suggests that high-urgency allocation of liver transplantation should be considered for ACLF

patients^[19,21]. Nonetheless, we note that not all patients with ACLF are transplant candidates for numerous reasons, which may include advanced age, active alcoholism, or concomitant diseases. The presence of non-liver organ failures may sometimes be a contraindication to liver transplantation^[3].

In conclusion, ACLF is a life-threatening syndrome and both the APASL and EASL criteria have identified ACLF patients with high short-term mortality. The clinical profile of ACLF patients in Singapore appears to have mixed features compared with similar studies reported in

the rest of Asia and the West. This would not be unique to Singapore, but applicable to many growing cities in Asia undergoing a rapid transformation from traditional disease epidemiology and lifestyle to improved living standards and widespread modern healthcare standards. Each region will have to re-evaluate their changing patterns of ACLF and address the new needs accordingly. The multi-ethnic composition of the Singapore population also has implications for understanding the variations in the Asian-Pacific region.

Patients with ACLF fulfilling only the APASL criteria in our study had significantly better survival rates compared with patients meeting the EASL criteria only, largely due to the APASL criteria accepting subjects who had chronic hepatitis but not liver cirrhosis (42.9%), while EASL-defined ACLF subjects must be cirrhotic. It is interesting to note that patients meeting the only APASL criteria had a higher MELD score than patients fulfilling the EASL criteria. These patients may have had a more severe acute insult leading to acute decompensation, but they still had higher survival rate due to better baseline liver function. Patients with ACLF fulfilling both criteria were more likely to have a fatal outcome (71.4% 3-mo mortality ($P = 0.041$)). CLIF-SOFA organ failure score, complemented by laboratory parameters such as creatinine, amylase, and INR appear to be promising tools in determining the prognosis of patients with ACLF. Early diagnosis of ACLF and identification of indicators predictive of poor outcome (as discussed above) will help to distinguish between patients with ACLF that would require transplantation from those that will survive with only organ support and intensive medical care^[14] and thus optimise treatment and survival.

COMMENTS

Background

Acute-on-chronic liver failure (ACLF) is a distinct disease entity with a high short-term mortality. There are two widely accepted diagnostic criteria for ACLF. However, there are crucial differences between them. There is also currently a lack of clear understanding of the natural history and clinical profile of the patients, which vary across different regions in the world.

Research frontiers

This is the first study to explore the applicability of the Asia-Pacific Association for the Study of the Liver (APASL) and European Association for the Study of the Liver (EASL) guidelines for ACLF in profiling patients and determining the outcome in Singapore.

Innovations and breakthroughs

EASL criteria may identify patients with a higher mortality. CLIF-SOFA organ failure score, complemented by laboratory parameters such as creatinine, amylase, and INR appear to be promising tools in determining the prognosis of patients with ACLF.

Applications

Early diagnosis of ACLF and identification of indicators predictive of poor outcome will help to distinguish between patients with ACLF that would require transplantation from those that will survive with only organ support and intensive medical care and thus optimise treatment and survival.

Terminology

ACLF: A distinct disease entity characterized by the acute deterioration of liver function in patients with the chronic liver disease.

Peer-review

The manuscript describes a retrospective study investigating ACLF in patients from Singapore. The study compared the EASL and APASL ACLF guidelines in patients with an acute decompensation of liver disease. The manuscript overall is of interest, and the results are enlightening.

REFERENCES

- Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS. Acute-on chronic liver failure. *J Hepatol* 2012; **57**: 1336-1348 [PMID: 22750750 DOI: 10.1016/j.jhep.2012.06.026]
- Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). *Hepatol Int* 2009; **3**: 269-282 [PMID: 19669378 DOI: 10.1007/s12072-008-9106-x]
- Arroyo V, Moreau R, Jalan R, Ginès P; EASL-CLIF Consortium CANONIC Study. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. *J Hepatol* 2015; **62**: S131-S143 [PMID: 25920082 DOI: 10.1016/j.jhep.2014.11.045]
- Olson JC, Kamath PS. Acute-on-chronic liver failure: concept, natural history, and prognosis. *Curr Opin Crit Care* 2011; **17**: 165-169 [PMID: 21326095 DOI: 10.1097/MCC.0b013e328344b42d]
- Kim TY, Kim DJ. Acute-on-chronic liver failure. *Clin Mol Hepatol* 2013; **19**: 349-359 [PMID: 24459638 DOI: 10.3350/cmh.2013.19.4.349]
- Department of Statistics, Ministry of Trade Industry, Republic of Singapore. Population Trends, 2016. ISSN 1793-2424
- Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013; **144**: 1426-1437, 1437.e1-1437.e9 [PMID: 23474284 DOI: 10.1053/j.gastro.2013.02.042]
- Vincent JL, Sakr Y. SOFA so good for predicting long-term outcomes. *Resuscitation* 2012; **83**: 537-538 [PMID: 22381650 DOI: 10.1016/j.resuscitation.2012.02.024]
- Jindal A, Rastogi A, Sarin SK. Reviewing the diagnostic criteria for acute-on-chronic liver failure. *Expert Rev Gastroenterol Hepatol* 2016; **10**: 1385-1395 [PMID: 27771965 DOI: 10.1080/17474124.2016.1250622]
- Bajaj JS. Defining acute-on-chronic liver failure: will East and West ever meet? *Gastroenterology* 2013; **144**: 1337-1339 [PMID: 23623966 DOI: 10.1053/j.gastro.2013.04.024]
- Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. *World J Gastroenterol* 2011; **17**: 3448-3452 [PMID: 21876637 DOI: 10.3748/wjg.v17.i29.3448]
- Pati GK, Singh A, Misra B, Misra D, Das HS, Panda C, Singh SP. Acute-on-Chronic Liver Failure (ACLF) in Coastal Eastern India: "A Single-Center Experience". *J Clin Exp Hepatol* 2016; **6**: 26-32 [PMID: 27194893 DOI: 10.1016/j.jceh.2015.08.002]
- Amarapurkar D, Dharod MV, Chandnani M, Baijal R, Kumar P, Jain M, Patel N, Kamani P, Issar S, Shah N, Kulkarni S, Gautam S, Shah A, Doshi S. Acute-on-chronic liver failure: a prospective study to determine the clinical profile, outcome, and factors predicting mortality. *Indian J Gastroenterol* 2015; **34**: 216-224 [PMID: 26080655 DOI: 10.1007/s12664-015-0574-3]

- 14 **Wlodzimirow KA**, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. *Liver Int* 2013; **33**: 40-52 [PMID: 22429562 DOI: 10.1111/j.1478-3231.2012.02790.x]
- 15 **Jalan R**, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. *Crit Care* 2012; **16**: R227 [PMID: 23186071 DOI: 10.1186/cc11882]
- 16 **Garg H**, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. *Dig Liver Dis* 2012; **44**: 166-171 [PMID: 21978580 DOI: 10.1016/j.dld.2011.08.029]
- 17 **Bahirwani R**, Shaked O, Bewtra M, Forde K, Reddy KR. Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes. *Transplantation* 2011; **92**: 952-957 [PMID: 21869735 DOI: 10.1097/TP.0b013e31822e6eda]
- 18 **Duan BW**, Lu SC, Wang ML, Liu JN, Chi P, Lai W, Wu JS, Guo QL, Lin DD, Liu Y, Zeng DB, Li CY, Meng QH, Ding HG, Chen XY, Liao HY, Ma LQ, Chen Y, Zhang J, Xiang HP, Duan ZP, Li N. Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive cases. *J Surg Res* 2013; **183**: 936-943 [PMID: 23558257 DOI: 10.1016/j.jss.2013.03.008]
- 19 **Finkenstedt A**, Nachbaur K, Zoller H, Joannidis M, Pratschke J, Graziadei IW, Vogel W. Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. *Liver Transpl* 2013; **19**: 879-886 [PMID: 23696006 DOI: 10.1002/lt.23678]
- 20 **Zheng MH**, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. *Clin Gastroenterol Hepatol* 2011; **9**: 351-356.e3 [PMID: 21195790 DOI: 10.1016/j.cgh.2010.12.027]
- 21 **Putignano A**, Gustot T. New concepts in acute-on-chronic liver failure: Implications for liver transplantation. *Liver Transpl* 2017; **23**: 234-243 [PMID: 27750389 DOI: 10.1002/lt.24654]

P- Reviewer: Bianchini M, Donnelly MC, Marchan-Lopez A, McMillin MA **S- Editor:** Gong ZM **L- Editor:** A
E- Editor: Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

